查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529613

癌症免疫學臨床試驗市場規模、佔有率和趨勢分析：按階段、設計、適應症、地區和細分市場預測，2024-2030

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

癌症免疫學臨床試驗市場成長與趨勢：

Grand View Research的最新報告顯示，到2030年，全球癌症免疫學臨床試驗市場規模預計將達到187億美元。

預計2024年至2030年該市場將以12.1%的複合年成長率擴張。快速發展的免疫腫瘤學領域已成為腫瘤生態系統中的一個新的治療領域，改變了癌症治療。

從2014年到2017年，新的免疫腫瘤學研究數量從250項增加到近600項，隨著藥物類別的多樣化，每年以兩位數的速度成長。這種快速成長的關鍵促進因素是生物標記和查核點抑制劑的測試。儘管免疫腫瘤學市場的多種藥理學類別正在日趨成熟，但細胞療法的成長速度超過了所有其他免疫療法。截至2020年3月，全球整體癌細胞治療產品線中有1,483種活性化合物，較2019年3月增加472種。成長最快的類別是嵌合體抗原受體T（CAR-T）細胞產品（2019年至2020年成長77%）。

此外，在COVID-19大流行期間，正在開發的IO藥物數量從2019年的3,876種增加到2020年的4,720種，分別比2019年和2017年增加了22%和233%。與 2018 年和 2017 年的 68% 相比，2019 年的 22% 增幅為 15%，這表明，儘管受到 COVID-19 大流行的影響，人們對 IO 的興趣有所恢復。

癌症免疫學臨床試驗市場報告亮點

  • 到 2023 年，III 期試驗將主導市場，佔最大佔有率，達到 53.2%。腫瘤學臨床試驗通常參與者較少，費用最高，且樣本大小較大，導致每位參與者的成本較高。
  • 2023年介入實驗佔78.5%以上的市場佔有率。
  • 2023年固態腫瘤領域佔收益佔有率為55.9%。這主要是由於固態腫瘤的盛行率不斷增加。
  • 北美地區主導市場，2020 年收益佔有率最大，為 50.3%。這是由於擴大採用以個人化醫療為重點的新型治療方法，以及政府的資助和投資。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章癌症免疫學臨床試驗市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 癌症免疫學臨床試驗市場分析工具
    • 波特的分析
    • PESTEL分析

第4章癌症免疫學臨床試驗市場：階段估計與趨勢分析

  • 細分儀表板
  • 癌症免疫學臨床試驗市場：相變分析，十億美元，2023-2030

第5章癌症免疫學臨床試驗市場：設計估算與趨勢分析

  • 細分儀表板
  • 癌症免疫學臨床試驗市場：設計變異分析，十億美元，2023 年和 2030 年

第6章 癌症免疫學臨床試驗市場：適應症估計及趨勢分析

  • 細分儀表板
  • 癌症免疫學臨床試驗市場：適應症變異分析，十億美元，2023 年和 2030 年

第7章癌症免疫學臨床試驗市場：區域估計與趨勢分析

  • 2023 年和 2030 年癌症免疫學臨床試驗市場佔有率（按地區），十億美元
  • 北美洲
    • 2018-2030年北美癌症免疫學臨床試驗市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年歐洲癌症免疫學臨床試驗市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年亞太地區癌症免疫學臨床試驗市場估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2018-2030年拉丁美洲癌症免疫學臨床試驗市場估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018-2030年中東與非洲癌症免疫學臨床試驗市場估計與預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • MEDPACE
    • Novartis
    • Exscientia
    • Syneous Health
    • AstraZeneca
    • IQ BIOTECH
    • BioNtech
    • IQVIA Holdings
    • ICON, Plc
    • Laboratory Corporation of America Holdings
簡介目錄
Product Code: GVR-4-68038-273-0

Immuno-oncology Clinical Trials Market Growth & Trends:

The global immuno-oncology clinical trials market size is expected to reach USD 18.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2024 to 2030. The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.

From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified. Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacological classes, cell therapies are exceeding all other immunotherapeutics in terms of growth. In March 2020, there were 1,483 active compounds in the pipeline for cancer cell therapy globally, indicating an increase of 472 from March 2019. The fastest-growing category was chimeric antigen receptor T (CAR-T) cell products (up 77% from 2019 to 2020).

Besides, during the Covid-19 pandemic, the number of IO drugs in development increased from 3,876 in 2019 to 4,720 in 2020, representing a 22% & 233% increase as compared to 2019 & 2017 respectively. After a moderate increase of 15% in 2019 compared to 68% between 2018 and 2017, this 22% increase indicates a return of interest in IO, despite the impact of the COVID-19 pandemic.

Immuno-oncology Clinical Trials Market Report Highlights:

  • Phase III dominated the market with the largest share of 53.2% in 2023. Oncology trials typically have fewer participants, are the most expensive, and involve larger sample sizes, resulting in a higher cost per participant.
  • The interventional experiments accounted for more than 78.5% of the market share in 2023
  • The segment of solid tumors held 55.9% of the revenue share in 2023. This is largely attributed to the rise in the prevalence of solid tumors
  • North America dominated the market and accounted for the largest revenue share of 50.3% in 2020. This is due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immuno-oncology Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immuno-oncology Clinical Trials Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immuno-oncology Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Immuno-oncology Clinical Trials Market: Phase Movement Analysis, USD Billion, 2023 & 2030
    • 4.2.1. Phase I
      • 4.2.1.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.2. Phase II
      • 4.2.2.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.3. Phase III
      • 4.2.3.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.4. Phase IV
      • 4.2.4.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Immuno-oncology Clinical Trials Market: Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Immuno-oncology Clinical Trials Market: Design Movement Analysis, USD Billion, 2023 & 2030
    • 5.2.1. Interventional Trials
      • 5.2.1.1. Interventional Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.2.2. Observational Trials
      • 5.2.2.1. Observational Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.2.3. Expanded Access Trials
      • 5.2.3.1. Expanded Access Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Immuno-oncology Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Immuno-oncology Clinical Trials Market: Indication Movement Analysis, USD Billion, 2023 & 2030
    • 6.2.1. Solid Tumors
      • 6.2.1.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.2.2. Hematological Cancer Healthcare
      • 6.2.2.1. Hematological Cancer Healthcare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Immuno-oncology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Immuno-oncology Clinical Trials Market Share, By Region, 2023 & 2030, USD Billion
  • 7.2. North America
    • 7.2.1. North America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. U.K. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. MEDPACE
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Novartis
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. Exscientia
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Syneous Health
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. AstraZeneca
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. IQ BIOTECH
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. BioNtech
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. IQVIA Holdings
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. ICON, Plc
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Laboratory Corporation of America Holdings
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives